Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
Author(s): Pier Luigi Zinzani 1,2;Catherine Thieblemont 3;Vladimir Melnichenko 4;Krimo Bouabdallah 5;Jan Walewski 6;Alejandro Majlis 7;Laura Fogliatto 8;A. Martin Garcia-Sancho 9;Beth Christian 10;Zafer Gulbas 11;Muhit Özcan 12;Guilherme Fleury Perini 13;Herve Ghesquieres 14;Margaret A. Shipp 15;Seth Thompson 16;Samhita Chakraborty 16;Patricia Marinello 16;Philippe Armand 15;
Source: Blood (2023) 142 (2): 141–145.
Dr. Maen Hussein's Thoughts
Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.
ABSTRACT
Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.Author Affiliations
1IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli,” Bologna, Italy;2Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy;3Department of Hemato-Oncology, Hôpital Saint-Louis APHP, Paris, France;4Department of Medical Oncology, Pirogov National Medical Surgical Center, Moscow, Russia;5Department of Hematology and Cellular Therapy, University Hospital, Bordeaux, France;6Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, European Reference Network, Warsaw, Poland;7Department of Hemato-Oncology, Clinica Alemana de Santiago, Santiago, Chile;8Department of Clinical Hematology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil;9Department of Hematology, Hospital Universitario de Salamanca, Institute of Biomedical Research of Salamanca, Centro de Investigación Biomédica en Red Cáncer, Salamanca, Spain;10Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH;11Department of Hematologic Oncology, Anadolu Medical Center, Gebze, Turkey;12Department of Hematology and Bone Marrow Transplantation Unit, Ankara University School of Medicine, Ankara, Turkey;13Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil;14Department of Clinical Hematology, Lyon-Sud Hospital Center, Lyon, France;15Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA;16Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ;Related Articles
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Another update demonstrated the superiority of polatuzumab vedotin plus R-CHOP (Pola-R-CHOP) over R-CHOP alone, with improved progression-free survival (PFS) (64% vs 59%). Overall survival (OS) was not statistically significant; however, the hazard ratio was 0.85, with greater benefit observed in high-risk patients.